Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2017 | Pages:
104 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape. Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology). - The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Sicca Syndrome (Sjogren) - Overview Sicca Syndrome (Sjogren) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Sicca Syndrome (Sjogren) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development Akari Therapeutics Plc Amgen Inc Atlantic Bio Sci LLC Bristol-Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd Galapagos NV Gilead Sciences Inc GlaxoSmithKline Plc Immunwork Inc MedImmune LLC Novartis AG Redx Pharma Plc Samjin Pharmaceutical Co Ltd UCB SA XTL Biopharmaceuticals Ltd Sicca Syndrome (Sjogren) - Drug Profiles abatacept - Drug Profile Product Description Mechanism Of Action R&D Progress ABS-11 - Drug Profile Product Description Mechanism Of Action R&D Progress AMG-557 - Drug Profile Product Description Mechanism Of Action R&D Progress belimumab - Drug Profile Product Description Mechanism Of Action R&D Progress belimumab + rituximab - Drug Profile Product Description Mechanism Of Action R&D Progress BMS-986142 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress CFZ-533 - Drug Profile Product Description Mechanism Of Action R&D Progress Coversin - Drug Profile Product Description Mechanism Of Action R&D Progress edratide - Drug Profile Product Description Mechanism Of Action R&D Progress filgotinib - Drug Profile Product Description Mechanism Of Action R&D Progress GS-9876 - Drug Profile Product Description Mechanism Of Action R&D Progress GSK-2618960 - Drug Profile Product Description Mechanism Of Action R&D Progress IMSO-001 - Drug Profile Product Description Mechanism Of Action R&D Progress leniolisib - Drug Profile Product Description Mechanism Of Action R&D Progress lulizumab pegol - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3090106 - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-4920 - Drug Profile Product Description Mechanism Of Action R&D Progress MEDI-7734 - Drug Profile Product Description Mechanism Of Action R&D Progress RDX-002 - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7625 - Drug Profile Product Description Mechanism Of Action R&D Progress RSLV-132 - Drug Profile Product Description Mechanism Of Action R&D Progress SA-001 - Drug Profile Product Description Mechanism Of Action R&D Progress seletalisib - Drug Profile Product Description Mechanism Of Action R&D Progress TE-2324 - Drug Profile Product Description Mechanism Of Action R&D Progress tirabrutinib - Drug Profile Product Description Mechanism Of Action R&D Progress VAY-736 - Drug Profile Product Description Mechanism Of Action R&D Progress VM-200 - Drug Profile Product Description Mechanism Of Action R&D Progress Sicca Syndrome (Sjogren) - Dormant Projects Sicca Syndrome (Sjogren) - Discontinued Products Sicca Syndrome (Sjogren) - Product Development Milestones Featured News & Press Releases Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjogren's Syndrome Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Sicca Syndrome (Sjogren), H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H1 2017 Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017 Sicca Syndrome (Sjogren) - Dormant Projects, H1 2017 Sicca Syndrome (Sjogren) - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
